Abstract. Patients with ischemic hearts who have refused coronary vascular reconstruction may exhibit dynamic myocardial remodeling and cardiac dysfunction. In the present study, the role of miRNA-1 and its association with the ubiquitin-proteasome system (UPS) in regulating myocardial remodeling was investigated. A myocardial infarction (MI) model was constructed and the hearts were treated with miRNA-1 antagomir, miRNA-1 lentiviral vectors and the UPS proteasome blocker bortezomib. The expression levels of miRNA-1 were evaluated using reverse transcription PCR and the abundance of the ubiquitin-proteasome protein and caspase-3 were evaluated via western blot analysis. Furthermore, the collagen volume fraction was calculated using Masson's trichrome staining, and the apoptosis index was detected via terminal deoxynucleotidyl transferase dUTP-biotin nick end labeling staining. Transforming growth factor (TGF)-β expression was assessed via immunohistochemical staining. Echocardiographic characteristics and myocardial infarct size were analyzed. miRNA-1 expression levels were found to be increased following MI. miRNA-1 antagomir administration clearly inhibited miRNA-1 expression, whereas the miRNA-1 lentiviral vector exerted the opposite effect. The expression levels of 19s proteasome, 20S proteasome and ubiquitin ligase E3 were decreased in the miRNA-1 antagomir group, but were significantly increased in the miRNA-1 lentiviral group; however, only 20S proteasome expression was decreased in the bortezomib group. Collagen hyperplasia and TGF-β expression were decreased in both the miRNA-1 antagomir and bortezomib groups, although the effects of the miRNA-1 antagomir were more noticeable. The miRNA-1 antagomir and the UPS proteasome blocker both alleviated the ultrastructural impairments, demonstrated by a decreased left ventricular (LV) end-diastolic diameter and LV mass, but the miRNA-1 antagomir was also able to increase LV ejection fraction and LV fractional shortening. miRNA-1 regulated UPS-associated mRNA expression and affected the majority of the UPS components in the myocardium, thereby leading to increased myocardial cell apoptosis, myocardial fibrosis and remodeling. The miRNA-1 antagomir exerted a more prominent cardioprotective effect compared with the UPS proteasome blocker bortezomib.

Introduction

Patients with ischemic hearts exhibit progressive myocardial remodeling, which is associated with massive cardiomyocyte loss, and for which an ideal therapeutic approach has yet to be identified (1,2). The pathological changes associated with ischemic hearts primarily involve cardiomyocyte apoptosis and myocardial fibrosis. The myocardial remodeling process includes myocardial cell apoptosis, necrosis, subsequent tissue fibrosis and, ultimately, heart failure, which is an inevitable consequence when patients are not treated in a timely manner, or if the patients cannot be revascularized (3). Substitution of apoptotic cardiomyocytes by collagen and fibrous tissue is an important cause of heart failure progression and myocardial remodeling. Stem cells and gene therapy may represent new strategies for blocking cardiac remodeling before it commences (4). It is advisable to prevent the progression of heart failure that occurs as a result of myocardial lesions by altering microRNA (miRNA) expression levels.

miRNAs are endogenous, non-coding small RNAs that regulate target genes at the post-transcriptional level and have been found to play an upstream regulatory role in the pathogenesis of heart failure (5-7). The most abundant miRNA in cardiac myocytes, and also the first miRNA to be implicated in heart development, is miRNA-1 (8,9). Accumulating
Evidence has demonstrated that cardiomyocyte apoptosis is closely associated with the abnormal expression of miRNA-1. Activation of caspases plays a central role in the execution phase of cell apoptosis (10), and caspase-3 is considered as the executioner of apoptosis. Previous studies demonstrated that there is a crucial interrelationship between caspase-3 activation and functional reserve in cardiomyocytes (11). It was also previously reported that miRNAs target caspase-3 in PANC-1 cells (12).

The expression of the UPS components, such as E2 conjugating enzymes, E3 ubiquitin ligases, or subunits of the proteasome, are either increased or decreased in cardiac disease. The expression levels of the UPS components are high in the impaired myocardium, and may be responsible for the degradation of the majority of senescent cellular proteins, as well as playing a key role in DNA repair (13-15). As defective protein degradation in human cardiomyopathies has been established, recent studies have started to address the potential underlying mechanisms. The overall observed increase in the expression of ubiquitination machinery in failing hearts may be in response to an increased protein burden, which may be attributed to the increased protein synthesis that accompanies the hypertrophic response, or to an excess of damaged or modified proteins to be targeted for proteasomal degradation (16,17). The association between these two systems remains to be fully elucidated.

The aim of the present study was to investigate the expression levels of miRNA-1 in mice with acute heart failure induced by acute ischemia, elucidate the role of miRNA-1 in myocardial remodeling and determine whether there is an association with the ubiquitin-proteasome system (UPS) in the regulation of heart remodeling following myocardial infarction (MI).

Materials and methods

MI model construction. A total of 48 male C57BL/6 mice, aged 6 weeks and weighing 25-30 g, were used in the present study. All animals were housed in an air-conditioned room (22±0.5°C) under a 12/12 h light-dark cycle with access to standard laboratory food and water ad libitum. After the mice were anesthetized by inhalation of 2% isoflurane, a skin incision was made over the left chest, followed by tying a suture knot around one-third of the left descending artery. The sham group underwent the same surgical procedure, except the suture placed under the left coronary artery was not tied. A control vector (30 µl), an miRNA-1 antagonir (30 µl, 1x10^9 TU/ml), an miRNA-1 lentiviral vector (30 µl, 1x10^9 TU/ml) and bortezomib (30 µg/kg) were delivered via intramyocardial injections, temporarily blanching the left ventricular (LV) anterior wall. The 48 mice were divided into the following groups (n=8 per group): i) Sham; ii) MI; iii) MI + control vector; iv) MI + miRNA-1 antagonir; v) MI + miRNA-1 lentiviral vector; and vi) MI + bortezomib. The protocol of the present study was approved by the Animal Ethics Committee of Tianjin Union Medical Center.

Antagomir of miRNA-1 and overexpression of miRNA-1. The antagonir method was used to block the expression of miRNA-1. A sequence of antisense oligonucleotides was designed (antagomir); the antisense nucleic acid was allowed to interact with the target miRNA, and then this was specifically intervened for downstream regulation. The miRNA-1 gene was overexpressed using lentiviral vectors. The small RNA gene and its side sequence were amplified from the genome and then cloned into lentiviral vectors. The lentivirus was named pPS-EF1-copGFP-LCS, and the reporter gene was green fluorescent protein (GFP); the antagonir and lentivirus were injected into the MI area and surrounding tissues. The antagonir and lentivirus were synthesized by Shanghai Ji Ma Biotechnology Co., Ltd.

Western blot assay evaluation. Total protein was extracted from tissues to detect the levels of caspase-3, 19S proteasome, 20S proteasome and ubiquitin ligase E3 in target tissue via western blotting. The proteins were separated via 12% SDS-PAGE, blotted and probed with rabbit anti-caspase-3 (1:500; Sigma-Aldrich), rabbit anti-19S proteasome (1:1,000; Enzo Life Sciences; cat. no. Q9SE12), rabbit anti-20S proteasome (1:1,000; Abcam; cat. no. ab22673) and rabbit anti-enzyme E3 (1:1,000; Abcam; cat. no. ab84067). A Bradford assay (Bio-Rad Laboratories, Inc.) was used to quantify protein concentrations. The blots were visualized using a chemiluminescence system (Amersham Bioscience; GE Healthcare).

Determination of myocardial cell apoptosis. Myocardial cell apoptosis was determined via terminal deoxyribonucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) staining, as previously described (18,19).

Masson's trichrome staining. Masson's trichrome staining was performed for histopathological observation. Following inhalation of 2% isoflurane, the hearts of the mice were isolated, perfused with normal saline followed by 4% paraformaldehyde for fixation, dehydrated with ethanol, coronally sectioned into halves along the long axis, embedded in paraffin blocks, consecutively cut into 5-µm sections, and then treated with commercial reagents for Masson's trichrome staining. Muscle fibers were stained purple-red, while collagen fibers were stained green-blue. Collagen volume fraction, calculated from Masson's trichrome staining images, was expressed as a percentage of the total LV myocardial volume.

Immunohistochemical staining. The expression of transforming growth factor (TGF)-β in the process of MI was observed via immunohistochemistry, which further revealed the degree of myocardial fibrosis and myocardial remodeling. Paraffin-embedded heart sections were used for the staining. Briefly, the sections were dewaxed, microwaved to retrieve antigens, blocked with 5% BSA, incubated overnight at 4°C with an isotype IgG control antibody, or with a rabbit anti-TGF-β (1:1,000; Cell Signaling Technology, Inc.; cat. no. 3711), and then hybridized with horseradish peroxidase-labeled secondary antibodies, followed by a 3,30-diaminobenzidine (DAB) chromogenic reaction. The brown DAB deposits were observed under a microscope.

Measurement of infarct size. After 2 weeks, the heart was frozen at -80°C and sliced transversely into 1-mm sections. The...
infarct size area (white area) and LV area were measured digitally using the Image Pro Plus software (Media Cybernetics, Inc.). Infarct size was expressed as a percentage of the white area/LV area.

Echocardiographic examination. After 2 weeks, echocardiography was performed using a high-resolution ultrasound imaging system. Anesthesia was induced with isoflurane 2% in 100% oxygen in an induction chamber. The sedated mice were studied using an echocardiography system (Sequoia Acuson, 15-MHz linear transducer; Siemens AG). The cardiac dimensions and function were assessed using M-mode echocardiography. LV end-diastolic diameter (LVDD) and LV end-systolic diameter were measured on the parasternal LV long axis view. LV fractional shortening (LVFS) was measured via the short axis view of the LV. LV ejection fraction (LVEF) and LV mass were calculated using computer algorithms. All measurements represent the mean of 5 consecutive cardiac cycles. All measurements were performed in a blinded manner.

Statistical analysis. All values and are expressed as mean ± standard deviation. Comparison between groups was subjected to analysis of variance followed by Tukey’s multiple comparison test. Two-sided tests were used and P<0.05 was considered to indicate a statistically significant difference. SPSS software (version 23.0; IBM Corp.) was used for the data analysis.

Results

Expression levels of miRNA-1 following miRNA-1 antagonist, miRNA-1 lentiviral vectors and bortezomib treatment. miRNA-1 antagonist, miRNA-1 lentiviral vector and the UPS proteasome blocker bortezomib were delivered via three separate intramyocardial injections. After 2 weeks, the border area tissue of the myocardial infarct from different groups was obtained in order to detect the miRNA-1 expression levels. miRNA-1 antagonist and miRNA-1 lentiviral models were successfully constructed and assessed via reverse transcription PCR. miRNA-1 expression levels were found to be significantly increased in the MI group (P<0.01) compared with the sham group (Fig. 1B). miRNA-1 expression was significantly decreased in the miRNA-1 antagonist group (P<0.01), whereas it was increased in the miRNA-1 lentiviral group (P<0.01). There was no significant difference between the bortezomib and control groups (Fig. 1B).

Expression levels of the UPS components following alterations in miRNA-1 expression and administration of bortezomib. The expression levels of the main component of the ubiquitin-proteasome, the 19S proteasome, were significantly increased in the MI group (P<0.01) compared with the sham group (Fig. 1A and C). The expression levels of the 19S proteasome were significantly decreased in the miRNA-1 antagonist group (P<0.05), increased in the miRNA-1 lentiviral group (P<0.05), and not significantly different in the bortezomib group when compared with the control group (Fig. 1A and C).

The expression levels of the 20S proteasome in the MI group were significantly increased (P<0.01) compared with those in the sham group (Fig. 1A and D). In addition, the 20S proteasome expression levels were significantly decreased in the miRNA-1 antagonist group (P<0.01), increased in the miRNA-1 lentiviral group (P<0.05), and also decreased in the bortezomib group (P<0.01) when compared with the control group (Fig. 1A and D).

The ubiquitin ligase E3 expression levels in the MI group were significantly increased (P<0.01) compared with those in the sham group (Fig. 1A and E). E3 expression was significantly decreased in the miRNA-1 antagonist group (P<0.01), significantly increased in the miRNA-1 lentiviral group (P<0.01), and not significantly different in the bortezomib group compared with the control group (Fig. 1A and E).

TUNEL staining following interference with the miRNA-1 expression levels and inhibition of the UPS. The number of apoptotic cells observed via TUNEL staining was significantly elevated in the MI group (P<0.01) compared with that in the sham group (Fig. 2A and B). The extent of apoptosis in the miRNA-1 lentiviral group was significantly increased (P<0.05) compared with the control group (Fig. 2A and B).

Caspase-3 expression following interference with the miRNA-1 expression levels and inhibition of the UPS. The expression levels of caspase-3 during MI were evaluated using western blotting, which further demonstrated the degree of myocardial cell in the different groups. Caspase-3 expression levels in the MI area were markedly increased in the MI group (P<0.01) compared with the sham group (Fig. 2C). Caspase-3 expression levels in the miRNA-1 antagonist group were markedly decreased (P<0.05), and there was no significant difference in the bortezomib group compared with the control group. The caspase-3 expression levels in the miRNA-1 lentiviral group were significantly higher (P<0.05) compared with those in the control group (Fig. 2C).

Masson’s staining following interference with miRNA-1 expression and administration of bortezomib. Masson’s trichrome staining was used to assess the degree of myocardial fibrosis. Microscopic examination revealed that the myocardial tissue was purple-red in color, whereas the fibrous tissue was green-blue. The myocardial fibers in the sham operation group were arranged in a regular manner; there were no abnormalities in the myocardial interstitium or myocardial intravascular region. Collagen hyperplasia, myocardial fiber disorder, and the proportion of green-blue-stained collagen was markedly increased in the MI group (P<0.01) compared with those areas in the sham group (Fig. 3A and B). Collagen hyperplasia and myocardial fiber disarray were markedly decreased in the MI group (P<0.01) and bortezomib (P<0.05) groups, but the bortezomib group exhibited fewer changes. Furthermore, collagen hyperplasia and myocardial fiber disarray were observed in the miRNA-1 lentiviral group. The fractional collagen volume in the miRNA-1 lentiviral group was significantly higher (P<0.01) compared with that in the control group (Fig. 3A and B).
miRNA-1 antagomir decreases infarct size in mice following MI. Infarct size was markedly higher in the MI group (P<0.01) compared with the sham group (Fig. 5A and B). Infarct size was markedly decreased in the miRNA-1 antagomir group (P<0.01), but was significantly larger in the miRNA-1 lentiviral group (P<0.01). There was no significant difference in the infarct size between the bortezomib and control groups (Fig. 5A and B).

Cardiac function changes following interference with miRNA-1 expression levels and inhibition of the UPS. The echocardiographic parameters revealed that LVEF (Fig. 2A and B), LVFS (Fig. 6A and C), LV mass (Fig. 6A and D) and LVDD (Fig. 6A and E) in the MI group exhibited significant changes (P<0.01) compared with the sham group. LVEF (Fig. 6A and B) and LVFS (Fig. 6A and C) were significantly increased in the miRNA-1 antagomir group (P<0.01), whereas LVEF (Fig. 6A and B) and LVFS (Fig. 6A and C) were decreased in the miRNA-1 lentiviral group (P<0.05), and were not significantly different in the bortezomib group compared with the control group.

LV mass (Fig. 6A and D) and LVDD (Fig. 6A and E) were significantly decreased in the miRNA-1 antagomir group (P<0.05), increased in the miRNA-1 lentiviral group (P<0.05), and mildly decreased in the bortezomib group (P<0.05) compared with the control group.

Discussion

Previous studies (20-22) support the hypothesis that miRNAs may play an important role in the upstream regulation of heart failure progression; however, the role of miRNAs in physiological and pathophysiological processes in the heart remains elusive.

The most abundant miRNA in cardiac myocytes, and the first miRNA to be implicated in heart development, is miRNA-1. miRNA-1 is encoded by two almost identical genes: miRNA-1-1 and miRNA-1-2, which are located within introns 2 and 12 of the E3 ubiquitin-protein ligase (23). Mice lacking the miR-1-2 gene develop various heart abnormalities.
Accumulating evidence suggests that cardiomyocyte apoptosis is associated with abnormal expression of miRNA-1. miRNAs that are present in the early phases of myocardial ischemia may be associated with cell death and oxidative stress (24). Transplanting miRNA-1-transfected embryonic stem cells (miRNA-1-1-ES) into the border zone of the infarct in mice.
significantly improved cardiac function (25). Cheng et al (26) revealed that serum miRNA-1 level increased rapidly following acute MI, reaching a peak value at 6 h, indicating a strong positive correlation between serum miRNA-1 levels and myocardial infarct size. Besser et al (27) reported that the miR-1/133a clusters were a prerequisite for maintaining specific functions in heart electrophysiology and may affect electrical conduction.

The UPS involves two steps: First, covalent attachment of ubiquitin to a target protein occurs via a cascade of chemical reactions catalyzed by the ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin ligases (E3). Second, the combination of ubiquitin proteins is recognized and degraded by the 26S proteasomes, and this is a principal pathway for the degradation of certain abnormal intracellular proteins (14,28,29). The 26S proteasome is composed of a 20S core and two 19S regulatory complexes. The UPS plays an important role in the removal of damaged proteins involved in the regulation of inflammation, cell proliferation and differentiation, signal transduction, transcriptional regulation, apoptosis and DNA repair, as well as other biological functions (30,31). Bortezomib is a dipeptide boronate proteasome inhibitor that reversibly binds to and inhibits the 20S proteasome (32,33).

There are a number of observations suggesting that certain E3-ligases play a key role in myocardial ischemia,
and that cardiomyocyte apoptosis is closely associated with the abnormal expression of miRNA-1 (6,17). For example, mice that were deficient in a co-chaperone with ubiquitin ligase properties, exhibited an accelerated age-associated pathophysiological phenotype and increased susceptibility to ischemia/reperfusion injury (34,35). miRNA-1 is located within introns 2 and 12 of the E3 ubiquitin-protein ligase. It is possible that the interaction between miRNA and UPS may be involved in the development of cardiovascular disease and myocardial remodeling (36-38); however, this interaction and its possible effects on the cardiovascular system require further investigation. Studies that assess the effect of miRNA-1 on the UPS in the development of heart failure and cardiac remodeling are currently limited.

In the present study, the expression levels of miRNA-1 increased following MI; in addition, miRNA-1 antagonir administration inhibited miRNA-1 expression, and miRNA-1 expression levels increased following injection of the miRNA-1 lentiviral vector, whereas the UPS proteasome blocker bortezomib was unable to modulate miRNA-1 expression. The 19S proteasome, 20S proteasome and ubiquitin ligase E3 in the miRNA-1 antagonir group decreased and then markedly increased following administration of the miRNA-1 lentiviral vector, but only 20S proteasome expression was decreased following delivery of the UPS proteasome blocker. These results demonstrated that miRNA-1 is able to affect all components of the UPS, while the UPS proteasome blocker bortezomib primarily affects the 20S proteasome. The miRNA-1 antagonist and bortezomib both alleviated the ultrastructural impairments, as demonstrated by a decreased LVDD and LV mass, but the effects of the miRNA-1 antagonir were more noticeable and also increased LVEF and LVFS. Furthermore, the opposite effect was observed in the miRNA-1 lentiviral vector group.

Cardiomyocyte apoptosis is one of the major pathological mechanisms underlying MI. Blocking the apoptosis process may prevent the loss of contractile cells and minimize cardiac injury. Thus, a TUNEL staining assay was performed and caspase-3 activity was measured using western blotting to investigate the underlying molecular mechanisms responsible for the improvement in cardiac function induced by administration of the miRNA-1 antagonir. The results indicated that the miRNA-1 antagonir inhibited cardiomyocyte apoptosis, as demonstrated by a decrease in TUNEL-positive cardiomyocytes and decreased caspase-3 expression levels, whereas the UPS proteasome blocker exerted no marked effect. By contrast, miRNA-1 lentiviral vector administration increased cardiomyocyte apoptosis and exacerbated myocardial injury. Masson's trichrome staining and TGF-β expression levels may be used to assess the degree of myocardial fibrosis and myocardial remodeling (39). In the present study, the decreased TGF-β expression levels in the miRNA-1 antagonir group compared with the control group indicate that miRNA-1 antagonir can inhibit fibrosis after myocardial infarction, while bortezomib did not exert noticeable effects. However, the administration of the miRNA-1 lentiviral vector enhanced the fibrotic responses.

A previous study reported that miRNA-1 levels are likely increased in the early stages of heart failure, that overexpression of miRNA-1 aggravates H2O2-induced cardiomyocyte apoptosis, while inhibition of miRNA-1 using antisense inhibitory oligonucleotides results in marked resistance to H2O2 (40). It was previously hypothesized that miRNA changes that occur
in the early phase of myocardial ischemia may be associated with cell death and oxidative stress, while those miRNAs altered in the later phase may contribute to post-infarct remodeling or function as compensatory mechanisms (41,42). Naga Prasad et al (43) selected a surgical mouse model of transverse aortic constriction to analyze alterations in eight miRNAs upon initiation of cardiac dysfunction, and discovered that the expression of miRNA-1 was decreased in end-stage heart failure. Profiling miRNAs across various tissues revealed that miRNA-1, let-7, miR-26a, miR-30c, miR-126-3p and miR-133 are highly expressed in the murine heart (44). The UPS regulates fundamental cell functions, including mitosis, DNA replication and repair, cell differentiation and transcriptional regulation, as well as receptor internalization, which all play crucial roles in heart biology (29). A previous study (17) demonstrated that the UPS function in patients with heart failure is altered, the protein degradation rate is reduced, and the balance between myocardial protein synthesis and degradation is disrupted, thus leading to an accumulation of modified proteins. UPS proteasome blockers were shown to inhibit nuclear factor-κB and exerted an anti-inflammatory cardioprotective effect. In addition, inadequate coupling between ubiquitination and proteasomal degradation appeared to be a major causative factor behind the UPS functional deficit that contributes to myocardial ischemic injury (45,46).

The present study indicated that the miRNA-1 antagonist exerted a significant protective effect on heart function, decreasing cardiomyocyte apoptosis and alleviating myocardial fibrosis and remodeling. The miRNA-1 antagonist exerted more prominent effects compared with the UPS proteasome blocker bortezomib. Studies on the association between ubiquitination and proteasomal degradation appeared to be a major causative factor behind the UPS functional deficit that contributes to myocardial ischemic injury (45,46).

In conclusion, the results of the present study suggest that the ubiquitin proteasomes may be the most important mediator of miRNA-1 in the regulation of heart remodeling. miRNA-1 was found to be associated with extensive expression of the UPS components in the myocardium, resulting primarily in changes in ubiquitin ligase E3 expression, leading to the accumulation of proteins, formation of a large number of ubiquitin-positive protein aggregates, increased myocardial cell apoptosis, and myocardial fibrosis or remodeling. Conversely, the miRNA-1 antagonist exerted a significant cardioprotective effect compared with the UPS proteasome blocker bortezomib. Thus, the present study underlines the fact that antisense silencing of miRNA-1 sequences that play a regulatory role in the development of heart failure may be a potential breakthrough in the treatment of heart failure.

Acknowledgements
Not applicable.

Funding
The present study was supported by the National Natural Science Foundation of China (grant no. 81200158), the Tianjin Health Bureau Key Project Fund (grant no. 16KG155) and the Tianjin Chronic Disease Prevention and Treatment Key Project (grant no. 16ZXJMSY00060).

Availability of materials and data
The datasets used or analyzed during the present study are available from the corresponding author on reasonable request.

Authors’ contributions
LW and XQ designed the experiments. LW and YZ drafted the manuscript. LW performed the experiments and collected the figures. All authors have read and approved the final version of the manuscript.

Ethics approval and consent to participate
The study protocol was approved by the Animal Ethics Committee of Tianjin Union Medical Center.

Patient consent for publication
Not applicable.

Competing interests
All the authors confirm that they have no competing interests.

References
1. Senni M, Paulus WJ, Gavazzi A, Fraser AG, Díez J, Solomon SD, Smiseth OA, Guazzi M, Lam CS, Maggioni AP, et al: New strategies for heart failure with preserved ejection fraction: The importance of targeted therapies for heart failure phenotypes. Eur Heart J 35: 2797-2815, 2014.
2. Majmudar MD, Keliher EJ, Heidt T, Leuschner F, Truelove J, Sena BF, Gorbakov R, Iwamoto Y, Dutta P, Wojtkiewicz G, et al: Monocyte-directed RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice. Circulation 127: 2038-2046, 2013.
3. Varela A, Mavroidis M, Katsimpoulas M, Sfiroera I, Kappa N, Mesa A, Kostomitsopoulos NG and Kokkinos DV: The neuroprotective agent rasagiline mesylate attenuates cardiac remodeling after experimental myocardial infarction. ESC Heart Fail 4: 331-340, 2017.
4. Sharp TE III, Schena GJ, Hobby AR, Starosta T, Berretta RM, Wallner M, Borghetti G, Gross P, Yu D, Johnson J, et al: Cortical bone stem cell therapy preserves cardiac structure and function after myocardial infarction. Circ Res 121: 1263-1278, 2017.
18. Zhang M, Rai D, Verma SK, Ghosh AK and Vaughan DE: MiR-125b is critical for fibroblast-to-myofibroblast transition and cardiac fibrosis. Circulation 133: 291-301, 2016.

19. Bud preg E, Kang ML, Dall’Pra S, Mirotosou M and Drazin VJ: MicroRNAs and cardiac regeneration. Circ Res 116: 1700-1711, 2015.

20. Zhang J, Lang Y, Guo L, Pei Y, Hua S, Liang Z, Su G, Shu L, Liu H, Huang C and Xu J: MicroRNA-1323a-3p promotes pressure overload-induced cardiac fibrosis by targeting TIMP3. Cell Physiol Biochem 411: 2176-2187, 2018.

21. Lee YE, Hong CY, Lin YL and Chen RM: MicroRNA-1 participates in nitric oxide-induced apoptotic insults to MCT3-EI cells by targeting heat-shock protein-70. Int J Mol Sci 11: 246-255, 2010.

22. Martinez EC, Llyanna S, Wang P, Vardy LA, Jiang X, Armsgam a, Jeyhelmathams AR: MicroRNA-1 activates a pro-adverse cardiac remodeling and dysfunction in ischemic heart disease. J Mol Cell Cardiol 112: 27-39, 2017.

23. Milliwain DR, Berger T and Mak TW: Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol 5: a008656, 2013.

24. Communal C, Sumandea M, de Tombe P, Narula J, Solaro RJ and Hajar RF: Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci USA 99: 6252-6256, 2002.

25. Park JK, Do sewff AI and Schmittgen TD: MicroRNAs targeting caspase-3 and -7 in FANC-1 cells. J Mol Biol 19: E1206, 2018.

26. Bronze-da-Rocha E: MicroRNAs expression profiles in cardiovascular diseases. Prog Mol Pathol 50: 2176-2187, 2018.

27. Schmidt M and Finley D: Regulation of protease activity in health and disease. Biochim Biophys Acta 1843: 13-25, 2014.

28. Gilda JE and Gomes AV: Proteasome dysfunction in cardiomyopathies. J Physiol 595: 4051-4071, 2017.

29. Ham QY, Wang HX, Liu CX, Gao CX, Hua Q, Yu HX, Li N, Yang YZ, Du J, Xia YL and Li HH: Circulating E3 ligases are novel and sensitive biomarkers for diagnosis of acute myocardial infarction. Clin Sci (Lond) 128: 751-760, 2015.

30. Zhang J, Sun D, Pan X, Zhan X, Zhu D, Li C, Zhang R, Gao E and Wang H: Lin2pa protects against cardiac ischemia/reperfusion injury in the diabetic mice through the insulin-PI3K-mTOR pathway. J Cell Mol Med 19: 1174-1182, 2015.

31. Wei L, Sun D, Yin Z, Yuan Y, Hwang A, Zhang Y, Si R, Zhang R, Guo W, Cao F and Wang H: A PKC-beta inhibitor protects against cardiac microvascular ischemia-reperfusion injury in diabetic rats. Apoptosis 15: 493-498, 2010.

32. Romaine SP, Tomaszewski M, Condorelli G and Samani NJ: MicroRNAs in cardiovascular disease: An introduction for clinicians. Heart 101: 921-928, 2015.

33. Wong LL, Wang J, Liew OW, Richards AM and Chen YT: MicroRNA-1 regulates cardiomyocyte apoptosis by modulating the PTEN/Akt pathway. Am J Physio Heart Circ Physio 315: e380-e388, 2018.

34. Dong S, Zhang Y, Li J, Liu X, Wang X, Wang D, Krall TJ, Delphin ES and Zhang C: MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem 284: 29514-29525, 2009.

35. Yeh YH, Hsu LA, Chen YH, Kuo CT, Chang GJ and Chen WJ: Protective role of heme oxygenase-1 in atrial remodeling. Basic Res Cardiol 111: 58, 2016.

36. Pang Y, Zhang J, Sun Y, Wu Z, Liu Z and Huang G: MicroRNA-1 regulates cardiomyocyte apoptosis by targeting Bcl-2. Int Heart J 50: 377-387, 2009.

37. Dong S, Cheng Y, Yang J, Li J, Liu X, Wang X, Wang D, Krall TJ, Delphin ES and Zhang C: MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem 284: 29514-29525, 2009.

38. Hu C, Tian Y, Xu H, Pan B, Terpstra EM, Wu P, Wang H, Li F, Liu J and Wang X: Inadequate ubiquitination-proteasome coupling contributes to myocardial ischemia-reperfusion injury. J Clin Invest 128: 5294-5306, 2018.

39. Adams B, Mapanga RF and Essop MF: Partial inhibition of the ubiquitin-proteasome system-regulated signal transduction. PLoS One 9: e113449, 2014.

40. Portbury AL, Ronnebaum SM, Zungu M, Patterson C and Willis MS: Back to your heart: Ubiquitin-proteasome system targets relevant signaling in the heart. J Mol Cell Cardiol 52: 526-537, 2012.

41. Pagan J, Seto T, Pagano M and Cittadini A: Role of the ubiquitin-proteasome system in the heart. Circ Res 112: 1046-1058, 2013.